Quick Takeaways:
- VetrixBio presented the first clinical data for VTX-304, an investigational bispecific antibody targeting NGF and ADAMTS-5, at the 6th International Veterinary Pain Short Course, highlighting its potential to address both pain and cartilage degeneration in canine osteoarthritis.
- In a natural osteoarthritis model using aged Beagles, a single 2.5 mg/kg subcutaneous dose of VTX-304 delivered pain relief comparable to bedinvetmab, as measured by the modified Canine Brief Pain Inventory (mCBPI).
- Preclinical biochemical and cell-based studies showed potent inhibition of the NGF/TrkA pathway and effective blockade of ADAMTS-5-mediated aggrecan cleavage, supporting the therapy’s potential for both analgesic and cartilage-protective effects in dogs with osteoarthritis.
Why It Matters?
VetrixBio is testing a dual-action osteoarthritis therapy that targets both pain (NGF/TrkA) and cartilage degradation (ADAMTS-5) in dogs, rather than just providing analgesia.
The clinical data in aged Beagles shows a single dose delivers pain relief comparable to the approved NGF inhibitor bedinvetmab, while preclinical studies support cartilage protection by blocking aggrecan cleavage. This positions VTX-304 as a potential next-generation OA drug that could differentiate from current monoclonal antibodies by offering both symptom control and structural benefit in canine osteoarthritis.
Source: PRnewswire
